BiBBInstruments

BiBBInstruments AB releases a video introducing the EndoDrill Model X, the first CE-marked electric endoscopy biopsy tool. It compares conventional manual EUS biopsy instruments and their limitations in obtaining sufficient tissue samples for cancer diagnosis.

BiBBInstruments announced approval for listing on AktieTorget, pending minimum subscription in its upcoming share issue and meeting market ownership requirements. Subscription for up to 13 MSEK begins September 21 and runs until October 5, with 4.6 MSEK already secured.

BiBBInstruments begins its share issue subscription period on September 21, 2017, for a planned listing on AktieTorget. The 13 MSEK issue, before costs, will fund commercialization of its product portfolio to improve diagnostics for common cancers.

BiBBInstruments, based in Medicon Village in Lund, completed a 4.6 MSEK share issue to fund commercialization of EndoDrill GI Upper, its first cancer diagnostics product. Founder Dr Charles Walther and LU Holding AB remain the largest shareholders, joined by ALMI Invest, Swedish Growth Fund, Fårö Capital AB, and private and institutional investors.

In August 2017, BiBBInstruments received CE marking for its first commercial biopsy instrument, EndoDrill GI Upper, enabling deliveries to Swedish hospitals that had pre-ordered. The company also secured new quotes at Kirurgveckan in Jönköping and prepared for a new share issue.

BiBB is a Swedish medtech company specializing in cancer diagnostics and develops EndoDrill, a patented series of the world’s first market-approved motorized biopsy instruments for endoscopic ultrasound.

Customer support: Fredrik Lindblad, CEO. Contact: +46 708 99 94 86, info@bibbinstruments.com

The EndoDrill biopsy tool is designed to improve cancer diagnostics by providing high-quality tissue samples for stomach, pancreatic, liver, lung, and bladder cancers. Its electric, rotating needle technology enables core biopsies during endoscopic ultrasound, overcoming limitations of current manual needles.